GREENVILLE, S.C.--(BUSINESS WIRE)--Avallano, an AI-enabled clinical research company, today announced the appointment of Michael A. Ibara, Pharm.D., as Chief Strategy Officer (CSO). Dr. Ibara will lead the company’s global strategic initiatives to transform the clinical trial sector with leading-edge technology solutions..

格林维尔，S.C.——（商业新闻短讯）——Avalano是一家人工智能支持的临床研究公司，今天宣布任命Michael A.Ibara，Pharm.D.为首席战略官（CSO）。Ibara博士将领导公司的全球战略计划，以前沿技术解决方案改造临床试验部门。。

Dr. Ibara will lead the launch of Avallano’s generative AI technologies, aimed at enhancing clinical research by addressing the challenges faced by patients, sites, and sponsors in executing clinical trials. Avallano’s solutions include personalized patient chat services, AI-driven medical information processing, founded on a market-leading approach to global privacy and patient empowerment.

Ibara博士将领导推出Avalano的生成人工智能技术，旨在通过解决患者、网站和赞助商在执行临床试验中面临的挑战来加强临床研究。Avalano的解决方案包括个性化患者聊天服务、人工智能驱动的医疗信息处理，这些服务建立在全球隐私和患者授权的市场领先方法之上。

He’ll guide the company in balancing regulatory compliance requirements with the capabilities of explainable AI..

他将指导公司平衡法规遵从性要求和可解释人工智能的能力。。

“Michael’s extensive experience in the biopharmaceutical industry and his innovative approach to data and clinical operations make him the perfect fit for Avallano,” said Paul Della Maggiora, Co-Founder and CEO. “We have already benefited from Michael’s strategic vision as an advisor and are confident that his leadership will help us achieve our ambitious goals and continue to provide exceptional service to our clients.”.

联合创始人兼首席执行官保罗·德拉·马吉拉（PaulDellaMaggiora）表示：“迈克尔在生物制药行业的丰富经验以及他对数据和临床操作的创新方法，使他非常适合阿瓦拉诺（Avalano）。”。“我们已经从迈克尔作为顾问的战略愿景中受益，相信他的领导将帮助我们实现雄心勃勃的目标，并继续为客户提供卓越的服务。”。

Prior to joining Avallano, Dr. Ibara served as Chief Data Officer at Elligo Health Solutions, where he created an innovative approach to utilize electronic health record (EHR) data for clinical trial feasibilities and operations. In addition to developing the first-ever effort to automate the collection of adverse events directly from EHRs, he has held senior leadership positions in large biopharmaceutical and CRO organizations.

在加入Avalano之前，Ibara博士曾担任Elligo Health Solutions的首席数据官，他在那里创建了一种创新方法，利用电子健康记录（EHR）数据进行临床试验的可行性和操作。除了首次尝试直接从EHR自动收集不良事件外，他还在大型生物制药和CRO组织中担任高级领导职务。

Dr. Ibara holds a Pharm.D. from the University of Michigan and a Fellowship from the University of North Carolina and Burroughs Wellcome Co..

伊巴拉博士拥有密歇根大学（University of Michigan）的药学博士学位，以及北卡罗来纳大学（University of North Carolina）和巴勒斯威康公司（Burroughs Wellcome Co.）的奖学金。。

“I am delighted to join Avallano at such an exciting time in the company’s growth,” said Dr. Ibara. “I look forward to working with the team to develop AI-driven solutions to improve clinical research and deliver innovative solutions to help patients get better value from participating in clinical trials.”.

伊巴拉博士说：“我很高兴在公司发展如此激动人心的时刻加入阿瓦拉诺。”。“我期待着与团队合作，开发人工智能驱动的解决方案，以改进临床研究，并提供创新解决方案，帮助患者从参与临床试验中获得更好的价值。”。

About Avallano

关于Avalano

Imagine a world where your life sciences data aren’t just numbers and figures but a powerful tool to drive engagement and education. We transform your data into actionable insights and harness its potential to create impactful patient and community engagement apps. We’re not just about data; we’re about making research benefits tangible and understandable to patients and communities.

想象一个世界，你的生命科学数据不仅是数字和数字，而且是推动参与和教育的有力工具。我们将您的数据转化为可行的见解，并利用其潜力创建有影响力的患者和社区参与应用程序。我们不仅仅关注数据；我们的目标是使研究成果对患者和社区来说切实可行和易懂。

Turn your data into action and unlock the true potential of your research network..

将数据转化为行动，释放研究网络的真正潜力。。